RPG Life Sciences Limited — PPTs, 08-11-2024: Investor Presentation

RPG Life Sciences has released its unaudited financial results for H1 FY25, showing robust performance across all business segments. Key highlights include revenue growth in Domestic Formulations (66% of sales), International Formulations (19%), and APIs (15%). The company maintains a debt-free status, with an upgraded credit rating. Future strategies focus on enhancing product portfolios, expanding market presence, and implementing digital transformation initiatives to drive operational efficiency and profitability.